S1 E2 - Abbott's Burton shares neuromodulation breakthroughs in diabetic peripheral neuropathy, chronic pain
AbbottTalks25 Jul 2023

S1 E2 - Abbott's Burton shares neuromodulation breakthroughs in diabetic peripheral neuropathy, chronic pain

In the newest episode of AbbottTalks, Allen Burton, Divisional VP and Chief Medical Officer of Neuromodulation at Abbott, shares insights into the company's innovative neuromodulation therapies. Burton delves into Abbott's FDA-approved treatment for chronic back pain, which uses electrical stimulation to alleviate pain, improve functionality, and reduce reliance on opioids. Burton discusses Abbott’s recent FDA approval to treat people who suffer from back pain with limited surgical options. He also expands on how the company's pioneering treatment for painful diabetic peripheral neuropathy, a condition affecting millions of Americans. This treatment uses electrical stimulation to dampen painful signals in the feet, enabling patients to regain mobility and control over their lives. Burton further introduces the Eterna SCS System, the smallest neurostimulation system in the market, which offers patients a low charging burden and indications for MRI compatibility. Listen to the full episode to hear directly from Abbott's Neuromodulation CMO on how Abbott's patient-centric neuromodulation therapies are impacting the lives of patients suffering from chronic pain and diabetic peripheral neuropathy.

Thank you to Resonant Link for sponsoring this episode of AbbottTalks. For more information about Resonant Link go to www.Resonant-Link.com.

Thank you for listening to the AbbottTalks Podcast. Click here to subscribe on your favorite podcast player: https://abbotttalks.castos.com/subscribe

Episoder(17)

S1 E1 - Abbott’s Adamson, Piorkowski share how tech can help heal and empower people with heart disease

S1 E1 - Abbott’s Adamson, Piorkowski share how tech can help heal and empower people with heart disease

In the opening episode of the DeviceTalks podcast network's newest podcast, AbbottTalks, Dr. Christopher Piorkowski, Divisional VP and Chief Medical Officer of Electrophysiology, and Dr. Philip Adamson, Divisional VP and Chief Medical Officer of Heart Failure, discuss the significant advancements in Abbott's cardiac technology and their forward-looking approach to cardiovascular care. Piorkowski sheds light on the profound impact of technology on patient outcomes in AFib treatment and underscores the importance of enhanced risk stratification tools and personalized therapy approaches. Adamson delves into the progress of Abbott's HeartMate series, specifically the HeartMate 3, highlighting its improved performance and reduced complications compared to its predecessors. Both Abbott leaders stress the essential role of implementation science and foresee an upward trend in enhanced patient identification to administer therapies like the HeartMate 3, aiming to reach patients across the disease spectrum who could significantly benefit from these advanced therapies. Listen now to AbbottTalks' first episode, and make sure to subscribe on all major podcast platforms to get the behind-the-scenes look at Abbott's transformative work across its diverse portfolio. This episode is sponsored by Coatings2Go. For more information go to Coatings2Go.com. Thank you for listening to the AbbottTalks Podcast. Click here to subscribe on your favorite podcast player: https://abbotttalks.castos.com/subscribe

16 Jun 202343min

Populært innen Politikk og nyheter

giver-og-gjengen-vg
aftenpodden
aftenpodden-usa
forklart
popradet
stopp-verden
dine-penger-pengeradet
det-store-bildet
bt-dokumentar-2
nokon-ma-ga
lydartikler-fra-aftenposten
fotballpodden-2
frokostshowet-pa-p5
rss-gukild-johaug
rss-ness
e24-podden
rss-penger-polser-og-politikk
tut-mediekjr
aftenbla-bla
rss-dannet-uten-piano